44 research outputs found

    Northern Entrepreneur\u27s Counterfeiting of Confederate Currency and The Impact It Had On Inflation

    Get PDF
    This thesis, Northern Entrepreneur\u27s Counterfeiting of Confederate Currency and The Impact It Had On Inflation takes an in depth look at the history of counterfeiting the currency of the Confederate States of America during the Civil War by entrepreneurs who saw the introduction of a new currency as an opportunity to profit. The thesis begins by providing background information on several major counterfeiters and their actions before and during the Civil War, as well as other sources of counterfeit bills not normally considered by scholars. The thesis also looks at the effects that this illegitimate increase in the money supply may have had on inflation in the South during the Civil War as well as the legal ramifications that the counterfeiter’s actions had in the North

    A reanalysis of the luminosities of clusters of galaxies in the EMSS sample with 0.3 < z < 0.6

    Full text link
    The X-ray luminosities of the Einstein Extended Medium Sensitivity Survey (EMSS) clusters of galaxies with redshifts 0.3<z<0.6 are remeasured using ROSAT PSPC data. It is found that the new luminosities are on average 1.18 +/- 0.08 times higher than previously measured but that this ratio depends strongly on the X-ray core radii we measure. For the clusters with small core radii, in general we confirm the EMSS luminosities, but for clusters with core radii >250 kpc (the constant value assumed in the EMSS), the new luminosities are 2.2 +/- 0.15 times the previous measurements. The X-ray luminosity function (XLF) at 0.3<z<0.6 is recalculated and is found to be consistent with the local XLF. The constraints on the updated properties of the 0.3<z<0.6 EMSS sample, including a comparison with the number of clusters predicted from local XLFs, indicate that the space density of luminous, massive clusters has either not evolved or has increased by a small factor ~2 since z=0.4. The implications of this result are discussed in terms of constraints on the cosmological parameter Omega_0.Comment: 12 pages, 7 figures. Accepted for publication in MNRA

    The HAT Score—A Simple Risk Stratification Score for Coagulopathic Bleeding During Adult Extracorporeal Membrane Oxygenation

    No full text
    Objective The study objective was to create an adult extracorporeal membrane oxygenation (ECMO) coagulopathic bleeding risk score. Design Secondary analysis was performed on an existing retrospective cohort. Pre-ECMO variables were tested for association with coagulopathic bleeding, and those with the strongest association were included in a multivariable model. Using this model, a risk stratification score was created. The score\u27s utility was validated by comparing bleeding and transfusion rates between score levels. Bleeding also was examined after stratifying by nadir platelet count and overanticoagulation. Predictive power of the score was compared against the risk score for major bleeding during anti-coagulation for atrial fibrillation (HAS-BLED). Setting Tertiary care academic medical center. Participants The study comprised patients who received venoarterial or venovenous ECMO over a 3-year period, excluding those with an identified source of surgical bleeding during exploration. Interventions None. Measurements and Main Results Fifty-three (47.3%) of 112 patients experienced coagulopathic bleeding. A 3-variable score—hypertension, age greater than 65, and ECMO type (HAT)—had fair predictive value (area under the receiver operating characteristic curve [AUC] = 0.66) and was superior to HAS-BLED (AUC = 0.64). As the HAT score increased from 0 to 3, bleeding rates also increased as follows: 30.8%, 48.7%, 63.0%, and 71.4%, respectively. Platelet and fresh frozen plasma transfusion tended to increase with the HAT score, but red blood cell transfusion did not. Nadir platelet count less than 50×103/µL and overanticoagulation during ECMO increased the AUC for the model to 0.73, suggesting additive risk. Conclusions The HAT score may allow for bleeding risk stratification in adult ECMO patients. Future studies in larger cohorts are necessary to confirm these findings

    CDI Blood Parameter Monitoring System 500—A New Tool for the Clinical Perfusionist

    No full text
    Sarns/3M Health Care has recently introduced the CDI 500 Blood Parameter Monitoring System. In addition to parameters previously available, this system now offers continuous monitoring of the patient’s oxygen consumption (VO2/min) and potassium concentration ([K+]). The purpose of this study was: (1) to compare the [K+] from the CDI 500 with the [K+] derived from our hospital’s laboratory; and (2) to compare the VO2/min from the CDI 500 with the results obtained utilizing the “gold-standard” Fick equation. The mean absolute difference in [K+] was 0.10 mEq/L with a mean percentage error of only 3.93%. The mean absolute difference in VO2/min was 18.78 ml O2/min, with a mean percentage error of 11.63%. We concluded that the [K+] correlated well and that 9.13% of the oxygen consumption percentage error was attributable to the exclusion of dissolved oxygen in the calculation used by the CDI 500, with the remaining 2.5% attributable to differences in technology. We recommended that future upgrades to the CDI 500 should include dissolved O2 when measuring oxygen consumption and consideration should be given to increasing the operating range for [K+]

    Platelet factor-4 concentration in adult veno-arterial ECMO patients

    No full text
    Background: Heparin induced thrombocytopenia (HIT) is reported at a variable rate in extracorporeal membrane oxygenation (ECMO) patients. A critical factor impacting platelet factor-4 (PF4)-heparin antibody formation is plasma PF4 concentration. We hypothesized that PF4 concentration would be increased during veno-arterial (VA) ECMO. Methods: Plasma PF4 concentration was measured during the first 5 ECMO days in 20 VA ECMO patients and 10 control plasma samples. PF4-heparin ratios were estimated using an assumed heparin concentration of 0.4 IU/mL. This correlates with an activated partial thromboplastin time of 60 to 80 seconds, which is the anticoagulation target in our center. Results: Twenty VA ECMO patients were enrolled, 10 of which had pulmonary embolism. Median PF4 concentration was 0.03 µg/mL [0.01, 0.13] in control plasma. Median PF4 concentration was 0.21 µg/mL [0.12, 0.34] on ECMO day 1 or 2, 0.16 µg/mL [0.09, 0.25] on ECMO day 3, and 0.12 µg/mL [0.09, 0.22] on ECMO day 5. Estimated median PF4-heparin ratios were 0.04, 0.03, and 0.02 respectively. Two patients (10%) developed HIT that was confirmed by serotonin release assay. PF4 concentration did not differ significantly in these patients compared to non-HIT patients (p = 0.37). No patient had an estimated PF4-heparin ratio between 0.7 and 1.4, which is the reported optimal range for PF4-heparin antibody formation. Conclusion: Our data suggest that PF4 concentration is mildly elevated during VA ECMO compared to control plasma. Estimated PF4-heparin ratios were not optimal for HIT antibody formation. These data support epidemiologic studies where HIT incidence is low during VA ECMO

    Taxonomic Description of Stenodiplosis tectori n. sp. (Diptera: Cecidomyiidae), a Seed Parasite of Cheatgrass, Anisantha tectorum, Based on Morphological and Mitochondrial DNA Data

    No full text
    Cheatgrass is an annual grass species from Eurasia that has become invasive in much of western North America. It has been implicated in recent increases in the frequency, size, and intensity of wildfires, contributing to severe economic, environmental, and social destruction. In order to reduce this damage, the USDA-ARS established a classical biological control program against cheatgrass. In 2018 and 2019, adult gall midges were collected emerging from cheatgrass seed heads collected at several sites in Bulgaria and Greece; this is the first gall midge ever recorded from cheatgrass. Morphological comparisons with related midge species recorded from other plant hosts revealed that this midge from cheatgrass is a new species, described here as Stenodiplosis tectori n. sp. This status was supported by sequence comparisons of a barcode region of the gene encoding the mitochondrial cytochrome c subunit I (CO1) protein in Stenodiplosis tectori n. sp. and three congeners. The present study is the first to report MT-CO1 data in the genus Stenodiplosis. The ingroup Stenodiplosis tectori n. sp. collected in the Balkans grouped in one phylogenetic supported clade, with an average K2P-distance from its closest related congener, S. sorghicola, of 7.73% (SD = 1.10). The findings indicated relatively high year-to-year within-population diversity. Implications for this gall midge’s utility as a biological control agent of cheatgrass are discussed

    Von Willebrand Factor Concentrate Administration for Acquired Von Willebrand Syndrome- Related Bleeding During Adult Extracorporeal Membrane Oxygenation

    No full text
    Objective: To review the use of Von Willebrand Factor (VWF) concentrate for treatment of acquired Von Willebrand syndrome (VWS)-related bleeding in adult extracorporeal membrane oxygenation (ECMO) patients and determine if it was associated with improved VWF laboratory parameters. Design: Retrospective observational cohort study. Setting: Tertiary care academic medical center. Participants: Adult ECMO patients who received VWF concentrate for treatment of acquired VWS- related bleeding. Interventions: None, observational study. Measurements and Main Results: Ten adult ECMO patients received VWF concentrate for treatment of bleeding with evidence of acquired VWS over a 15-month period. Six patients were on veno-arterial ECMO and 4 were on veno-venous ECMO. The most common site of bleeding was airway or tracheal bleeding. The mean dose of VWF concentrate was 41 IU/kg. Mean VWF antigen was 263 ± 93 IU/dL before treatment and 394 ± 54 after treatment. Mean ristocetin cofactor activity was 127 ± 47 IU/dL before treatment and 240 ± 33 after treatment. The mean VWF ristocetin cofactor activity antigen ratio increased from 0.52 ± 0.14 before treatment to 0.62 ± 0.04 after treatment. Four of 10 patients had complete resolution of their bleeding within 24 hours, and 6 of 10 had complete resolution of their bleeding within 2- to- 4 days. There were 3 patients who had thrombotic events potentially related to VWF concentrate administration. No patient had an arterial thrombosis, stroke, or myocardial infarction. Conclusions: VWF concentrate administration increases VWF function in adult ECMO patients, but also may be associated with increased thrombotic risk. Larger studies are needed to determine VWF concentrate\u27s safety, efficacy, and optimal dosing in adult ECMO patients
    corecore